- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.02. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 03.02. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 21.01. | Silexion Therapeutics Corp: Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit | 2 | GlobeNewswire (USA) | ||
| 06.01. | Silexion Therapeutics Corp: Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 | 298 | GlobeNewswire (Europe) | SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company's Platform Seeks to Address an Estimated... ► Artikel lesen | |
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.01. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 16.12.25 | Silexion Therapeutics Corp: Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| 16.12.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 02.12.25 | Silexion Therapeutics Corp: Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | Silexion Therapeutics Corp: Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer | 374 | GlobeNewswire (Europe) | Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains... ► Artikel lesen | |
| 25.11.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Silexion Therapeutics GAAP EPS of -$2.88 | 2 | Seeking Alpha | ||
| 12.11.25 | Silexion Therapeutics Corp Announces Drop In Q3 Bottom Line | 3 | RTTNews | ||
| 12.11.25 | Silexion Therapeutics Corp: Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | 597 | GlobeNewswire (Europe) | Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell... ► Artikel lesen | |
| 12.11.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Silexion Therapeutics Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.09.25 | Silexion Therapeutics Corp: Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer | 214 | GlobeNewswire (Europe) | New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence... ► Artikel lesen | |
| 25.09.25 | Silexion regains Nasdaq compliance, advances cancer therapy program | 1 | Investing.com | ||
| 25.09.25 | Silexion Therapeutics Corp: Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements | 191 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 25.09.25 | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,95 | +0,44 % | Opening Bell: BioNTech, Hewlett Packard Enterprise, NIO, Oracle, Adobe | Die US-Börsen haben am Montag im Handelsverlauf ins Plus gedreht. Der Dow Jones schloss 0,50 Prozent höher, nachdem er zunächst schwächer gestartet war. Der Nasdaq Composite legte sogar 1,38 Prozent... ► Artikel lesen | |
| AMGEN | 321,50 | +0,23 % | Wenn das eigene Immunsystem die Augen angreift / Biotechnologieunternehmen Amgen setzt auf Forschung für Patient:innen mit seltenen Erkrankungen | München (ots) - Die endokrine Orbitopathie ist eine seltene und potenziell sehkraftbedrohende Autoimmunerkrankung. Mit einem zielgerichteten Forschungsansatz nach seinem "Biology first"-Prinzip baut... ► Artikel lesen | |
| NOVAVAX | 8,923 | -0,34 % | Jefferies reiterates Buy on Novavax stock, cites adjuvant platform | ||
| BIOGEN | 160,90 | -0,12 % | Biogen Inc.: Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy | New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapySalanersen... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,280 | -0,03 % | Jefferies bestätigt Kaufempfehlung für Viking Therapeutics mit Kursziel von 101 US-Dollar | ||
| MAINZ BIOMED | 0,720 | -0,80 % | Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY | BERKELEY, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber, today announced, effective upon the commencement of trading on March 12, 2026... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,130 | -0,36 % | Intellia Therapeutics auf der Leerink-Konferenz: Gen-Editing-Therapie Lonbo-Z mit hohem Margenpotenzial | ||
| TEMPUS AI | 43,800 | 0,00 % | Cathie Wood's ARK sells LY Corp stock, buys Tempus AI | ||
| BIOCRYST PHARMACEUTICALS | 7,252 | +0,11 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 51,16 | -0,12 % | BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents | ||
| SAREPTA THERAPEUTICS | 14,420 | +0,28 % | Mizuho raises Sarepta Therapeutics stock price target to $31 | ||
| EXELIXIS | 35,630 | -1,33 % | Exelixis auf Barclays-Konferenz: Strategisches Wachstum und Einblicke in die Pipeline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,148 | -1,15 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,900 | +2,16 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| VAXART | 0,566 | 0,00 % | Vaxart signals $700M COVID-19 vaccine milestone path as Sanofi partnership advances and 2026 data readouts approach |
SILEXION THERAPEUTICS CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,830 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.